From time to time on Neurosurgery Blog, you will see us cross-posting or linking to items from other places when we believe they hit the mark on an issue. Since we are smack-dab in the middle of our focus on topics related to vascular neurosurgery, we wanted to bring attention to study which recently appeared in Neurosurgery, the official journal of the Congress of Neurological Surgeons, which publishes research on clinical and experimental neurosurgery covering the very latest developments in science, technology and medicine.
In March of 2019,
Neurosurgery published, “Surgical Performance Determines Functional Outcome
Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen
Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure,” which
highlights the results of the MISTIE III trial.
According to a University of Chicago Medicine press release, the MISTIE III trial “is the first study to identify specific surgical goals for the treatment of an intracerebral hemorrhage — the deadliest and most disabling type of stroke — a team of neurosurgeons found that at least 70 percent of the hemorrhage has to be removed for patients to make a meaningful recovery.”
To read the full Neurosurgery article, click here.
Editor’s Note: We
encourage everyone to join the conversation online by using the hashtag #VascularNeurosurgery.
